The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables

Basit Öğe Kaydı
dc.contributor.authorTuran, Gulay
dc.contributor.authorUsta, Ceyda Sancakli
dc.contributor.authorUsta, Akin
dc.contributor.authorKanter, Mehmet
dc.contributor.authorTavli, Lema
dc.contributor.authorKaracan, Meric
dc.contributor.authorCelik, Cetin
dc.date.accessioned2020-03-26T18:58:37Z
dc.date.available2020-03-26T18:58:37Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOvarian cancer is the most common cause of death among all gynecologic malignancies and a result of complex interaction of multiple oncogenes and tumor suppressor genes. The aim of this study was to evaluate expression of HER-2/neu (c-erbB2), survivin and cycline D1 biomarkers in serous ovarian neoplasms and their correlations with clinicopathological variables in serous ovarian cancers. We analyzed pathological specimens of 62 patients with benign (n = 25), borderline (n = 14) and malignant (n = 23) serous ovarian neoplasms. Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded specimens. Significantly more immunoreactivity with HER-2/neu was detected in malignant tumors (100 %) compared to borderline (78.6 %) and benign tumors (48 %) (P < 0.01). Survivin expression was significantly higher in malignant tumors (91.3 %) than those found in borderline (71.4 %) and benign tumors (24 %) (P < 0.001). Similarly, higher cyclin D1 expression was observed in malignant tumors (95.6 %) compared to borderline (85.7 %) and benign tumors (48 %) (P < 0.001). Expression of all biomarkers analyzed significantly and gradually increased from benign to borderline and borderline to malignant serous tumors. In terms of clinicopathological variables, only tumor grade was associated with the expression of all biomarkers others exhibited different correlations in serous ovarian cancers. The expressions of HER-2/neu (c-erbB2), survivin and cycline D1 are positively correlated with the malignant potential of serous ovarian neoplasms.en_US
dc.identifier.doi10.1007/s10735-014-9591-2en_US
dc.identifier.endpage687en_US
dc.identifier.issn1567-2379en_US
dc.identifier.issn1567-2387en_US
dc.identifier.issue6en_US
dc.identifier.pmid25106503en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage679en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s10735-014-9591-2
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31208
dc.identifier.volume45en_US
dc.identifier.wosWOS:000344750300007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofJOURNAL OF MOLECULAR HISTOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectSerous ovarian neoplasmsen_US
dc.subjectHER-2/neu (c-erbB2)en_US
dc.subjectSurvivingen_US
dc.subjectCycline D1en_US
dc.subjectImmunohistochemistryen_US
dc.titleThe expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variablesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu